Effect of Oscillation Techniques on Breathing in COPD Patients
The Effect of Airway Oscillation and Chest Wall Oscillation on Respiratory Functions and Sleep Quality in COPD Patients in Acute Exacerbation Period and Technical Inspection of Devices
NA · Saglik Bilimleri Universitesi · NCT06274957
This study tests whether two different breathing devices can help people with COPD who are having a flare-up feel better by reducing their cough and mucus.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 27 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | Saglik Bilimleri Universitesi (other) |
| Locations | 1 site (Istanbul) |
| Trial ID | NCT06274957 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of airway and chest wall oscillation techniques on respiratory functions in patients experiencing acute exacerbations of chronic obstructive pulmonary disease (COPD). It aims to compare the effectiveness of two specific devices: a positive expiratory pressure (PEP) device and a high-frequency chest wall oscillation (HFCWO) device. The trial will involve 33 hospitalized patients diagnosed with COPD exacerbation, who will be monitored for improvements in symptoms such as cough and sputum production. The study seeks to fill a gap in existing literature regarding device technologies used during COPD exacerbations.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 40 and older with a diagnosis of COPD exacerbation classified as GOLD stage 3 or 4.
Not a fit: Patients with asthma attacks, pulmonary fibrosis, or other significant lung conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved respiratory function and symptom relief for patients suffering from acute COPD exacerbations.
How similar studies have performed: While traditional exercise training has shown benefits for COPD patients, this specific comparison of oscillation techniques is novel and has not been extensively studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Being classified as GOLD stage 3 or 4 based on spirometric evaluation in the medical history. * Having a hospital admission within the specified time frame, evaluated by a pulmonary specialist, and admitted to the pulmonary diseases service with a diagnosis of COPD exacerbation. * Being 40 years of age or older. * Voluntarily agreeing to participate in the study. Exclusion Criteria: * Having a hospital admission with a diagnosis of asthma attack in the last 5 years. * Monitoring suspicious focal points for pneumonia on lung radiology. * Hospitalization due to reasons other than exacerbation despite having a diagnosis of COPD. * Presence of pulmonary fibrosis or suspicious findings of fibrosis on radiology. * Systemic fungal infections. * Having cognitive impairment affecting the decision to participate in the study, such as confusion, orientation disorder, or dementia. * Patients with lung cancer or metastasis in the lungs. * Diagnosis of conditions provoking shortness of breath other than COPD exacerbation, such as pneumonia, pneumothorax, heart failure, and pulmonary embolism. * Presence of a new-onset rhythm disorder or ischemic changes requiring intervention on the EKG, excluding sinus tachycardia and multifocal atrial tachycardia. * Chronic kidney failure requiring hemodialysis. * Patients with conditions causing weakness in the lower extremities, such as arthritis, neurological disease, deep vein thrombosis, peripheral artery disease, muscle weakness, fractures, osteoarthritis, etc. * Having ankylosing spondylitis with a Cobb angle of 10 degrees or more in the radiographic evaluation of the vertebral column. * Having undergone surgery on the upper extremities, lower extremities, neck, and back.
Where this trial is running
Istanbul
- University of Health Sciences — Istanbul, Turkey (RECRUITING)
Study contacts
- Principal investigator: GAMZE KOYUTURK, PT, PHD (C) — SAGLIK BILIMLERI UNI
- Study coordinator: Zuhal KUNDURACILAR, PROF. DR.
- Email: zuhal.kunduracilar@sbu.edu.tr
- Phone: +905302195286
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: COPD Exacerbation Acute, copd, pep, hfcwo, airway clearance techniques